ArticleInfection and drug resistance2025
Loop-Mediated Isothermal Amplification (LAMP) for Rapid and Sensitive Detection of Carbapenemase Genes in CRE: A Diagnostic Validation Study.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phenotypic and Genetic Characteristics ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical utility of loop-mediated isothermal amplification (LAMP) for detecting carbapenemase genes in carbapenem-resistant Enterobacteriaceae (CRE). Methods: From January 2023 to December 2024, 112 clinical CRE isolates were collected, including 104 carbapenem-resistant Klebsiella pneumoniae (CR-KP), 7 Escherichia coli (CR-EC), and 1 Klebsiella oxytoca (CR-KO). These isolates were obtained primarily from sputum (n=65), urine (n=29), and bronchoalveolar lavage fluid (n=9). The isolates were predominantly isolated from neurosurgery (38.39%), intensive care unit (21.42%), and respiratory critical care medicine (15.18%). Carbapenemase genes were detected in parallel using both sequencing (reference standard) and LAMP methods under blinded conditions. Statistical analysis included cross-tabulation and Cohen's kappa coefficient for agreement assessment. Results: Among the 112 CRE isolates, 96.43% (108/112) carried carbapenemase resistance genes. KPC variants predominated (89/108, 82.4%), including blaKPC-2 (n=87) and blaKPC-33 (n=2). NDM variants were detected in 29 isolates (26.9%), comprising blaNDM-1 (n=14) and blaNDM-5 (n=15). OXA-48 was identified in 3 isolates (2.8%). Compared with sequencing, LAMP demonstrated perfect sensitivity (100%) for all three gene types, with specificities of 91.30% (KPC), 96.38% (NDM), and 100% (OXA-48). However, the performance data for OXA-48 should be considered preliminary due to the low number of positive isolates (n=3).The kappa values indicated excellent agreement: 0.943 (KPC), 0.932 (NDM), and 1.000 (OXA-48). Conclusion: LAMP technology shows high diagnostic accuracy for detecting major carbapenemase genes particularly KPC and NDM in CRE isolates, offering a reliable tool for guiding appropriate antibiotic therapy. Its operational simplicity and cost-effectiveness make it particularly suitable for implementation in primary healthcare settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.